REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. 1ST AMENDMENT OF THE RESEARCH AND OPTION...Research and Option Agreement • April 25th, 2024 • CureVac N.V. • Pharmaceutical preparations
This 1st Amendment (“Amendment”) to the Research and Option Agreement (“Agreement”) is made and entered into effective as of 12 January 2023 (the “Effective Amendment Date”) by and between CureVac SE, Friedrich-Miescher-Str. 15, 72076 Tübingen, Germany, and myNEO NV, Ottergemsesteenweg Zuid 808 box 511, 9000 Ghent, Belgium.
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. SEVENTH AMENDMENT TO SPONSORED RESEARCH...Sponsored Research Agreement • April 25th, 2024 • CureVac N.V. • Pharmaceutical preparations
This seventh amendment to Agreement (the “Seventh Amendment”), is effective as of February 23, 2024 (“Seventh Amendment Effective Date”), by and between The Schepens Eye Research Institute, Inc., a not-for-profit Massachusetts corporation, having a principal place of business at 20 Staniford Street, Boston, Massachusetts 02114 (“SERI”), and Massachusetts Eye and Ear Infirmary, having a principal place of business at 243 Charles Street, Boston, Massachusetts 02114 (“MEEI”) (collectively, SERI and MEEI shall be referred to herein as “Hospitals”), and CureVac SE, a European Company, having a principal place of business at Friedrich-Miescher-Straße 15, 72076 Tübingen, Germany (“Sponsor”), each herein referred to as a “Party” and collectively as the “Parties”. Capitalized terms that are not defined herein shall have the meaning ascribed to them in the Agreement (as defined below).
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. 2nd Amendment to the DEVELOPMENT AND LICENSE...Development and License Agreement • April 25th, 2024 • CureVac N.V. • Pharmaceutical preparations
WHEREAS, The Parties wish to amend the Agreement, as amended, by adding the [*****] Program, Program 3 and Program 4 (each defined below).
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. SIXTH AMENDMENT TO SPONSORED RESEARCH...Sponsored Research Agreement • April 25th, 2024 • CureVac N.V. • Pharmaceutical preparations
This sixth amendment to Agreement (the “Sixth Amendment”), is effective as of June 29, 2023 (“Sixth Amendment Effective Date”), by and between The Schepens Eye Research Institute, Inc., a not-for-profit Massachusetts corporation, having a principal place of business at 20 Staniford Street, Boston, Massachusetts 02114 (“SERI”), and Massachusetts Eye and Ear Infirmary, having a principal place of business at 243 Charles Street, Boston, Massachusetts 02114 (“MEEI”) (collectively, SERI and MEEI shall be referred to herein as “Hospitals”), and CureVac SE, a European Company, having a principal place of business at Friedrich-Miescher-Straße 15, 72076 Tübingen, Germany (“Sponsor”), each herein referred to as a “Party” and collectively as the “Parties”. Capitalized terms that are not defined herein shall have the meaning ascribed to them in the Agreement (as defined below).
Amendment Four to Development and Option AgreementDevelopment and Option Agreement • April 25th, 2024 • CureVac N.V. • Pharmaceutical preparations
This Amendment Four to the Development and Option Agreement (this "Amendment"), dated as of February 13, 2024 (the "Amendment Four Effective Date"), is made by and between CureVac SE, a German stock corporation with offices at Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany ("CureVac"), and Acuitas Therapeutics Inc., a British Columbia corporation with offices at 6190 Agronomy Road, Suite 405, Vancouver, British Columbia, V6T 1Z3, Canada ("Acuitas") and amends the Development and Option Agreement dated April 29, 2016, as amended by Side Agreement and Amendment Number One dated December 1, 2016, Amendment Two to the Development and Option Agreement dated July 10, 2020, and Amendment Three dated December 24, 2020 by and between CureVac and Acuitas (collectively as amended, the “D&O Agreement”).
